Current understanding of polymyxin B applications in bacteraemia/sepsis therapy prevention: Clinical, pharmaceutical, structural and mechanistic aspects

Anti-Infective Agents in Medicinal Chemistry

Volumn 8, Issue 4, 2009, Pages 367-385

  Garidel, Patrick ^a   Brandenburg, Klaus ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Anti infective agent; Biophysics; Endotoxin; Lipopolysaccharide; LPS; PMB; PME; Polymyxin; Sepsis

Indexed keywords

ALGINIC ACID; BACTERIUM LIPOPOLYSACCHARIDE; CHITOSAN; COLISTIN; LIPOSOME; MEROPENEM; POLYMYXIN B;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; CONTROLLED DRUG RELEASE; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; ENCAPSULATION; ENDOTOXEMIA; ENTEROBACTERIACEAE; EXTRACORPOREAL CIRCULATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HEMOPERFUSION; HOSPITAL INFECTION; HUMAN; HYPOTENSION; INTENSIVE CARE; LUNG INFECTION; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; PHASE TRANSITION; PSEUDOMONAS INFECTION; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SALMONELLA MINNESOTA; SEPSIS; SEPTIC SHOCK; SURFACE PLASMON RESONANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERMODYNAMICS; TRACHEOBRONCHITIS; URINARY TRACT INFECTION; VETERINARY MEDICINE; ZETA POTENTIAL;

EID: 73549087461     PISSN: 18715214     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152109789760171     Document Type: Review

References (156)

1. Storm, D.R.; Rosenthal, K.S.; Swanson, P.E. Polymyxin and related peptide anti-biotics. Ann. Rev. Biochem., 1977, 46, 723.
2. Evans, M. E.; Feola, D. J.; Rapp, R. P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother., 1999, 33, 960.
3. Gales, A. C.; Jones, R. N.; Sader, H. S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin. Microbiol. Infect., 2006, 12, 315.
4. Michalopoulos, A.; Falagas, M. E. Colistin and Polymyxin B in Crit. care. Crit. Care Clin., 2008, 24, 377.
5. Falagas, M. E.; Kasiakou, S. K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care, 2006, 10, R27.
6. Falagas, M. E.; Kasiakou, S. K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Rev. Anti-infect. Agents, 2005, 40, 1333.
7. Zavascki, A.P.; Goldani, L.Z.; Cao, G.; Superti, S.V.; Lutz, L.; Barth, A.L.; Ramos, F.; Boniatti, M.M.; Nation, R.L.; Li, J. Pharmacokinetics of intravenous polymyxin B in Crit.ly ill patients. Clin. Infect. Dis., 2008, 47 , 1298.
8. Zavascki, A. P.; Goldani, L. Z.; Li, J.; Nation, R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: A Crit. review. J. Antimicrob. Chemother., 2007, 60, 1206.
9. Hornef, M. W.; Wick, M. J.; Rhen, M.; Normark, S. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat. Immunol., 2002, 3; 1033.
10. Moskowitz, S. M.; Ernst, R. K.; Miller, S. I. PmrAB, a two component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol., 2004, 186, 575.
11. Winfield, M. D.; Groisman, E. A. Phenotypic differences between Salmonella and Escherichia coli resulting from the disparate regulation of homologous genes. Proc. Natl. Acad. Sci. USA, 2004, 101, 17162.
12. Brodsky, I. E.; Ernst, R. K.; Miller, S. I. Mig-14 is a Salmonella gene that plays a role in bacterial resistance to antimicrobial peptides. J. Bacteriol., 2002, 184, 3203.
13. Campos, M. A.; Vargas, M. A.; Regueiro V. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect. Immun., 2004, 72, 7107.
14. Loutet, S. A.; Flannagan, R. S.; Kooi, C. A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. J. Bacteriol., 2006, 188, 2073.
15. Tran, A. X.; Whittomore, J. D.; Wyrick, P. B. The lipid A 1-phosphatase of Helicobacter pylori is required for resistance to the antimicrobial peptide polymyxin. J. Bacteriol., 2006, 188, 4531.
16. Winfield, M. D.; Latifi, T.; Groisman, E. A. Transcriptional regulation of the 4-amino-5-deoxy-L-arabinose biosynthetic genes in Yersinia pestis. J. Biol. Chem., 2005, 280, 14765.
17. Mathur, J.; Waldor, M. K. The Vibrio cholera ToxR-regulated porin OmpU confers resistance to antimicrobial peptides. Infect. Immun., 2004, 72, 3577.
18. Bedford Laboratories. Polymyxin B for injection (package insert), OH 44146. Bedford Laboratories, 2004, at http:// dailymed.nlm.nih.gov.
19. Garidel, P.; Andrä, J.; Howe, J.; Gutsmann, T.; Brandenburg, K. Novel anti-inflammatory and antiinfective agents. Anti-Infect. Agents Med. Chem., 2007, 6, 185.
20. Beutler, B.; Rietschel, E. Th. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev., 2003, 3, 169.
21. Evans, M. E., Pollack, M. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J. Infect. Dis. , 1993, 1336.
22. Cooperstock, M.S. Inactivation of endotoxin by polymyxin B. Antimicrob. Agents Chemother., 1974, 6, 422.
23. David, S. A. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J. Mol. Recognit., 2001, 14; 370.
24. Nahra, R.; Dellinger, R. P. Targeting the lipopolysaccharides: still a matter of debate? Curr. Opin. Anesthesiol., 2008, 21, 98.
25. Cunha, B. A. New uses for older antibiotics: Nitrofurantoin, Amikacin, Colistin, Polymyxin B, Doxycycline, and Minocycline revisited. Med. Clin. North Am., 2006, 90, 1089.
26. Fenner, T. Therapie von Infektionen. Erregerspektrum, Diagnostik, Behandlungsschemata. 2. Auflage, Schattauer GmbH: Stuttgart, 2003.
27. Andrä, J.; Gutsmann, T.; Garidel, P.; Brandenburg, K. Mechanisms of endotoxin neutralization by synthetic compounds. J. Endotox. Res., 2006, 12, 261.
28. Kwa, A.; Kasiakou, S. K.; Tam, V. H.; Falagas, M. E. Polymyxin B: Similarities to and differences from colistin (polymyxin E). Expert Rev. Anti-Infect. Ther., 2007, 5 (5), 811.
29. Lynn, W. A. Anti-endotoxin Ther.eutic options for the treatment of sepsis. J. Antimicrob. Chemother., 1998, 41, (Suppl. A), 71.
30. Tam, V.; Schilling, A.; Vo, G. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2005, 49, 3624.
31. Nation, R. L.; Li, J. Optimizing use of colistin and polymyxin B in the Crit.ly ill. Semin. Respir. Crit. Care Med., 2007, 28, 604.
32. [32 Consensus Conference Committee. American College of Chest Physicians / Society of Crit. Care Medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative Ther.ies in sepsis. Crit. Care Med., 1992, 20, 864.
33. Levy, M. M.; Fink, M. P.; Marshall, J. C.; Abraham, E.; Angus, D.; Cook, D.; Opal, S. M.; Vincent, J. L.; Ramsay, G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med., 2003, 31; 1250 and published in Intensive Care Med., 2003, 29, 530.
34. Vincent, J. L.; Habib, A. M.; Verdant, C.; Bruhn, A. Sepsis diagnosis and management: work in progress. Minerva Anestesiol., 2006, 72, 87.
35. Moerer, O.; Schmid, A.; Hofmann, M.; Herklotz, A.; Reinhart, K.; Wedan, K.; Schneider, H.; Burchardi, H. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med., 2002, 28, 1440.
36. Remick, D. G. Pathophysiology of sepsis. Biological perspectives. Am. J. Pathol., 2007, 170, 1435.
37. Jacobi, J. Pathophysiology of sepsis. Am. J. Health-Syst. Pharm., 2002, 59, S3.
38. Brandenburg, K.; Jürgens, G., Andrä, J.; Lindner, B.; Koch, M .H. J.; Blume, A.; Garidel, P. Biophysical characterization of the interaction of high-density lipoprotein (HDL) with endotoxins. Eur. J. Biochem., 2002, 269, 5972.
39. Brandenburg, K.; Garidel, P.; Andrä, J.; Jürgens, G.; Müller, M.; Blume, A.; Koch, M. H. J.; Levin, J. Cross-linked hemoglobin converts endotoxically inactive pentaacyl endotoxins into a physiologically active conformation. J. Biol. Chem., 2003, 278, 47660.
40. Jürgens, G.; Müller, M.; Garidel, P.; Koch, M. H. J.; Nakakubo, H.; Blume, A.; Brandenburg, K. Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A. J. Endotox. Res., 2002, 8, 115.
41. Hornef, M. W.; Henriques-Normark, Normak, S. The function and biological role of toll-like receptors in infectious diseases: an update. Current Opinion Infect. Dis., 2008, 21, 304.
42. Bhor, V. M.; Thomas, C. J.; Surolia, N.; Surolia, A. Polymyxin B: An ode to an old antidote for endotoxic shock. Mol. BioSyst., 2005, 1, 213.
43. Brandenburg, K.; Andrä, J.; Müller, M.; Koch, M. H. J.; Garidel, P. Physicochemical properties of bacterial glycopolymers in relation to bioactivity. Carbohydrate Res., 2003, 338, 2477.
44. Holst, O. The structures of core regions from enterobacterial lipopolysaccharides - An update. FEMS Microbiol. Lett., 2007, 271, 3.
45. Rietschel, E. Th.; Seydel, U.; Zähringer, U.; Schade, U. F.; Brade, L.; Loppnow, H.; Feist, W.; Wang, M.-H.; Ulmer, A. J.; Flad, H.-D.; Brandenburg, K.; Kirikae, T.; Grimmecke, D.; Holst, O.; Brade, H. Bacterial endotoxin: Molecular relationships between structure and activity. Infect. Dis. Clin. North Am., 1991, 5, 753.
46. Seydel, U.; Hawkins, L.; Schromm, A. B.; Heine, H.; Scheel, O.; Koch, M. H. J.; Brandenburg, K. The generalized endotoxic principle. Eur. J. Immunol., 2003, 33, 1586.
47. Brandenburg, K.; Hawkins, L.; Garidel, P.; Andrä, J.; Müller, M.; Heine, H.; Koch, M. H. J.; Seydel, U. Structural polymorphism and endotoxic activity of synthetic phospholipid-like amphiphiles. Biochemistry, 2004, 43, 4039.
48. Schromm, A. B.; Howe, J.; Ulmer, A. J.; Wiesmüller, K.-H.; Seyberth, T.; Jung, G.; Rössle, M.; Koch, M. H. J.; Gutsmann, T.; Brandenburg, K. Physicochemical and biological analysis of synthetic bacterial lipopeptides: Validity of the concept of endotoxic conformation. J. Biol. Chem., 2007, 282, 11030.
49. Schromm, A. B.; Brandenburg, K.; Loppnow, H.; Zähringer, U.; Rietschel, E. Th.; Carroll, S. F.; Koch, M. H. J.; Kusumoto, S.; Seydel, U. The charge of endotoxin molecules influences their conformation and interleukin-6 inducing capacity, Eur. J. Biochem., 2000, 161, 5464.
50. Schromm, A. B.; Brandenburg, K.; Rietschel, E. T.; Seydel, U. Do endotoxin aggregates intercalate into phospholipid membranes in a nonspecific, hydrophobic manner? J. Endotox. Res., 1995, 2, 313.
51. Mueller, M.; Lindner, B.; Kusumoto, S.; Fukase, K.; Schromm, A. B.; Seydel, U. Aggregates are the biologically active units of endotoxin. J. Biol. Chem., 2004, 279, 26307.
52. Brandenburg, P.; Garidel, P.; Gutsmann, T. In: Physicochemical properties of microbial glycoploymers. Moran, A.; Holst, O.; Brennan, P.; von Itzstein, M. Eds, Microbial Glykobiology, Elsevier 2009, Chapter 38, pp. 759-779.
53. Schürholz, T.; Marx, G. Management of sepsis. Minerva Anesthesiol., 2008, 74, 181.
54. Wheeler, A.P.; Bernard, G.R. Treating patients with severe sepsis. N. Engl. J. Med., 1999, 340, 207.
55. Marx, G.; Schuerholz, T.; Reinhart, K. Intensivmedizinische Aspekte bei Sepsis. Chirurg, 2005, 76, 845.
56. Mackenzie, I.; Lever, A. Management of sepsis. Br. Med. J., 2007, 335, 929.
57. Weigand, M. A.; Bardenheuer, H. J.; Böttiger, B. W. Klinisches Management bei Patienten mit Sepsis. Der Anaesthesist, 2003, 52, 3.
58. Dellinger, R.; Levy, M. M.; Carlet, J. M.; Bion, J.; Parker, M. M.; Jaeschke, R.; Reinhart, K.; Angus, D. C.; Brun-Buisson, C.; Beale, R.; Calandra, T.; Dhainaut, J. F.; Gerlach, H.; Harvey, M.; Marini, J. J.; Marshall, J.; Ranieri, M.; Ramsay, G.; Sevransky, J.; Thompson, T.; Townsend, S.; Vender, J. S.; Zimmerman, J. L.; Vincent, J. L. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Crit. Care Med., 2008, 36, 296.
59. Bernard, G. R. Sepsis trials: intersection of investigation, regulation, funding, and practice. Am. J. Respir. Crit. Care Med., 1995, 152, 4.
60. Landman, D.; Georgescu, C.; Martin, D. A.; Quale, J. Polymyxins revisited. Clin. Microbiol. Rev., 2008, 21, 449.
61. Bergen, P. J.; Rayner, C. R.; Nation, R. L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 2006, 50, 1953.
62. Yuan, Z.; Tam, H. Polymyxin B: a new strategy for multidrugresistant Gram-negative organisms. Expert Opin. Investig. Drug, 2008, 17, 661.
63. Horton, J.; Pankey, G. A. Polymyxin B, colistin, and sodium colistimethate. Med. Clin. North Am., 1982, 66, 135.
64. Hogardt, M.; Schmoldt, S.; Götzfried, M.; Adler, K.; Heesemann, J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother., 2004, 54, 1057.
65. Li, J.; Turnidge, J.; Milne, R.; R. L. Nation; K. Coulthard. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother., 2001, 45, 781.
66. Seltmann, G.; Lindner, B.; Holst, O. Resistance of Serratia marcescens to polymyxin B: A comparative investigation of two Sform lipopolysaccharides obtained from a sensitive and a resistant variant of strain 111. J. Endotox. Res., 1996, 3, 497.
67. Ko, K. S.; Suh, J. Y.; Kwon, K. T.; Jung, S.-I.; Park, K.-H.; Kang, C. I.; Chung, D. R.; Peck, K. R.; Song, J.-H. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother., 2007, 60, 1163.
68. Antoniadou, A.; Kontopidou, F.; Poulakou, G. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother., 2007, 59, 786.
69. Michalopoulos, A.; Kasiakou, S. K.; Rosmarakis, E. S.; Falagas, M. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand. J. Infect. Dis., 2005, 37, 142.
70. Sarria, J. C.; Angulo-Pernett; F.; Kimbrough, R. C.; McVay, C. S.; Vidal, A. M. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur. J. Clin. Microbiol. Infect. Dis., 2004, 23, 340.
71. Goverman, J.; Weber, J. M.; Keaney, T. J.; Sheridan, R. L. Intravenous colistin for the treatment of multidrug resistant, Gramnegative infection in the paediatric population. J. Burn Care Res., 2007, 28, 421.
72. Sobieszczyk, M.; Yoko Furuya, E.; Hay, C. M.; Pancholi P.; Della-Latta, P.; Hammer, S. H.; Kubin, C. J. Combination Ther.y with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J. Antimicrob. Chemother., 2004, 54, 566.
73. Holloway, K. P.; Rouphael, N. G.; Wells, J. B.; King. M. D.; Blumberg, H. M. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann. Pharmacother., 2006, 40, 1939.
74. Furtado, G. H. C.; d' Azevedo, P. A.; Santos, A. F.; Gales, A. C.; Pignatari, A. C. C.; Medeiros, E. A. S. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrugresistant Pseudomonas aeruginosa. Int. J. Antimicrob. Agents, 2007, 30, 315.
75. Pastewski, A. A.; Caruso, P.; Parris, A. R.; Dizon, R.; Kopec, R.; Sharma, S.; Mayer, S.; Ghitan, M.; Chapnick, E. K. Parenteral polymyxin B use in patients with multidrug-resistant Gram-negative bacteraemia and urinary tract infections: A retrospective case series. Ann. Pharmacother., 2008, 42, 1177.
76. Pereira, G. H.; Muller, P. R.; Levin, A. S. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn. Microbiol. Infect. Dis., 2007, 58, 235.
77. Zhou, B.-P.; Lu, J.; Qiu, C.; Wu, S.-P.; Song, W.-D.; Yang, D.-G.; Fu, Y.-Y.; Gao, X.; Liu, X.-Y.; Liu, S.-T.; Lu, P.-X.; Shan, W.-S.; Li, Y.-M.; Yuan, G.-Y.; Zhong, N.-S. The treatment of multidrugresistant Pseudomonas aeruginosa with polymyxin B or E in a patient with the highly pathogenic avian influenza A (H5N1) infection: A case report and review of the literature. Chin. J. Antibiot., 2007, 32, 685.
78. Markou N, Apostolakos H, Koumoudiou C.; Athanasiou, M.; Koutsoukou, A.; Alamanos, I. ; Gregorakos, L. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in Crit.ly ill patients. Crit Care, 2003, 7, R78.
79. Karabinis, A.; Paramythiotou, E.; Mylona-Petropoulou, D.; Kalogeromitros, A.; Katsarelis, N.; Kontopidou, F.; Poularas, I.; Malamou-Lada, H. Colistin for Klebsiella pneumoniae-associated sepsis. Clin. Infect. Dis., 2004, 38, e7.
80. Kopterides, P.; Koletsi, P.; Morfou; P.; Rellos; K.; Mastora; Z.; Rizos; M.; Falagas, M. Exposure to fluoroquinolones is a risk factor for polymyxins-only susceptible (POS) Acinetobacter baumannii bacteraemia in Crit.ly ill patients. Int. J. Antimicrob. Agents, 2007, 30, 409.
81. Kollef, M. H. An empirical approach to the treatment of multidrugresistant ventilator associated pneumonia. Clin. Infect. Dis., 2003, 36, 1119.
82. Cruz, D. N.; Perazella, M. A.; Bellomo, R.; de Cal, M.; Polanco, N.; Corradi, V.; Lentini, P.; Nalesso, F.; Ueno, T.; Ranieri, V. M.; Ronco, C. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit. Care, 2007, 1, R47.
83. Cruz, D. N.; Bellomo, R.; Ronco, C. Clinical effects of polymyxin B-immobilized fibre column in septic patients. Contrib. Nephrol., 2007, 156, 444.
84. Shoji, H.; Tani, T.; Hanasawa, K.; Kodama, M. Extracorporeal endotoxin removal by polymyxin B immobilized fibre cartridge: Designing and antiendotoxin efficacy in the clinical application. Ther. Apher., 1998, 2, 3.
85. Teramoto, K.; Nakamoto, Y.; Kunitomo, T.; Shoji, H.; Tani, T.; Hanazawa, K.; Kodama, M. Removal of endotoxin in blood by polymyxin B immobilized polystyrene-derivative fibre Ther. Apher., 2002, 6, 103.
86. Tani, T. Review of endotoxin-adsorbing direct hemoperfusion therapy using a column containing polymyxin B immobilized fibre. Curr. Opin Crit. Care, 2000, 6, 416.
87. Ruberto, F.; Pugliese, F.; D' Alio, A.; Martelli, S.; Bruno, K.; Marcellino, V.; Summonti, D.; Celli, P.; Perrella, S.; Cappannoli, A.; Pietropaoli, C.; Tosi, A.; Diana, B.; Novelli, G.; Rossi, M.; Ginanni Corradini, S. ;Ferretti, G.; Berloco, P. B.; Pietropaoli, P. Clinical effects of direct hemoperfusion using a polymyxin-B immobilized column in solid organ transplanted patients with signs of severe sepsis and septic shock. A pilot study. Int. J. Artif. Organs, 2007, 30, 915.
88. Ruberto, F.; Pugliese, F.; D' Alio, A.; Martelli, S.; Bruno, K.; Marcellino, V.; Perrella, S.; Cappannoli, A.; Mazzarino, V.; Tosi, A.; Novelli, G.; Rossi, M.; Ginanni Corradini, S.; Ferretti, G.; Berloco, P. B.; Pietropaoli, P. Clinical effects of use Polymyxin B fixed on fibers in liver transplant patients with severe sepsis or septic shock. Transplant. Proc., 2007, 39, 1953.
89. Kakugawa, T.; Mukae, H.; Saito, M.; Ishii, K.; Ishimoto, H.; Sakamoto, N.; Takazono, T.; Fukuda, Y.; Ooe, N.; Kohno, S. Rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin Bimmobilized fibre column hemoperfusion. Int. Med., 2008, 47, 785.
90. Murakami, M.; Miyauchi, Y.; Nishida, M.; Okada, H.; Hamano, K. Early initiation of polymyxin B-immobilized fiber Ther.y effective for septic shock after aortic replacement. Ann. Thorac. Cardiovasc. Surg., 2007, 13, 287.
91. Sakamoto, Y.; Mashiko, K.; Obata, T.; Matsumoto, H.; Hara, Y.; Kutsukata, N.; Yamamoto, Y. Clinical responses and improvement of some laboratory parameters following polymyxin Bimmobilized fibre treatment in septic shock. ASAIO J., 2007, 53, 646.
92. Sakamoto, Y.; Mashiko, K.; Obata, T.; Matsumoto, H.; Hara, Y.; Kutsukata, N.; Yamamoto, Y. Effectiveness of continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter after polymyxin B-immobilized fibre column therapy of septic shock. ASAIO J., 2008, 54, 129.
93. Cantaluppi, V.; Assenzio, B.; Pasero, D.; Romanazzi, G. M.; Pacitti, A.; Lanfranco, G.; Puntorieri, V.; Martin, E. L.; Mascia, L.; Monti, G.; Casella, G. Segoloni, G. P.; Camussi, G.; Ranieri, V. M. Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med., 2008, 34, 1638.
94. Naka, T.; Shinozaki, M.; Akizawa, T.; Shima, Y.; Takaesu, H.; Nasu, H. The effect of continuous veno-venous hemofiltration or direct hemoperfusion with polymyxin B-immobilized fibre on neutrophil respiratory oxidative burst in patients with sepsis and septic shock. Ther. Apher. Dial., 2006, 10, 7.
95. Nakamura, T.; Kawagoe, Y.; Ueda, Y.; Node, K.; Koide, H. Polymyxin B-immobilized fibre haemoperfusion reduces urinary 8-hydroxy-2′- deoxyguanosine levels in patients with septic shock. (2006) Clin. Intensive Care, 2006, 17, 95.
96. Kase, Y.; Obata, T.; Okamoto, Y.; Iwai, K.; Saito, K.; Yokoyama, K.; Takinami, M.; Tanifuji, Y. Removal of 2-arachidonylglycerol by direct hemoperfusion Ther.y with polymyxin B immobilized fibers benefits patients with septic shock. Ther. Apher. Dial., 2008, 12, 374.
97. Shimizu, T.; Hanasawa, K.; Sato, K.; Umeki, M.; Koga, N.; Naganuma, T.; Sato, S.; Shimonishi, T.; Ikeda, T.; Matsuno, N.; Ono, S.; Saitoh, H.; Satoh, K.; Otani, Y.; Endo, Y.; Eguchi, Y.; Tani, T. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbeck's Arch. Surg., 2008, pp. 1-9.
98. Kushi, H.; Miki, T.; Sakagami, Y.; Sato, J.; Saito, T.; Tanjoh, K. Early hemoperfusion with a polymyxin B column improves gastric intramucosal pH in sepsis. Ther. Apher. Dial., 2008, 12, 278.
99. Ohki, S.; Oshima, K.; Takeyoshi, I.; Matsumoto, K.; Morishita, Y. Endotoxin removal with a polymyxin B-immobilized hemoperfusion cartridge improves cardiopulmonary function after cardiopulmonary bypass. J. Surg. Res., 2008, 145, 74.
100. Komatsu, S.; Shimomatsuya, T.; Nakajima, M.; Ono, S.; Maruhashi, K. Severity scoring systems for prognosis and efficacy of polymyxin B-immobilized fibre treatment for colonic perforation. Surg. Today, 2006, 36, 807.
101. Morishita, Y.; Kita, Y.; Ohtake, K.; Kusano, E.; Hishikawa, S.; Mizuta, K.; Kawarasaki, H. Successful treatment of sepsis with polymyxin B-immobilized fibre hemoperfusion in a child after living donor liver transplantation. Digest. Dis. Sci., 2005, 50, 757.
102. Ronco, R. The place of early haemoperfusion with polymyxin B fibre column in the treatment of sepsis. Crit. Care, 2005, 9, 631.
103. Giacometti, A.; Cirioni, O.; Ghiselli, R.; Mocchegiani, F.; Paggi, A.M.; Orlando, F.; Kamysz, W.; Kasprzykowski, F.; Maćkiewicz, Z.; Scalise, G.; Saba, V. Ther.eutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock. J. Antimicrob. Chemother., 2002, 49, 193.
104. Moriyama, N.; Miyoshi, M.; Imoto, T.; Maruyama, M.; Shido, O.; Watanabe, T. Systemic administration of polymyxin B induces hypothermia in rats via an inhibitory effect on metabolic rate. Eur. J. Pharmacol., 2006, 541, 38.
105. Rybníček, J.; Hill, P.B. Suspected polymyxin B-induced pemphigus vulgaris in a dog. Vet. Dermatol., 2007, 18, 165.
106. Oshima, K.; Akao, T.; Kobayashi, K.; Muraoka, M.; Matsumoto, K.; Takeyoshi, I. The effect of direct hemoperfusion with a polymyxin B-immobilized fibre column (DHP-PMX Ther.y) on pulmonary ischemia-reperfusion injury in a canine model. J. Invest. Surgery, 2008, 21, 127.
107. Nakanowatari, Y.; Nemoto, K.; Hara, S.; Ninomiya, N.; Yamamoto, Y. Effects of direct haemoperfusion through fibres immobilizing polymyxin B and nafamostat mesilate on endotoxaemia in conscious guinea-pigs. Clin. Expert Pharmacol. Physiol., 2008, 35, 17.
108. Yamamoto, H.; Koizumi, T.; Kaneki, T.; Fujimoto, K.; Kubo, K.; Honda, T. Direct hemoperfusion with polymyxin B-immobilized fiber improves shock and hypoxemia during endotoxemia in anesthetized sheep. J. Endotox. Res., 2002, 8, 418.
109. Morresey, P. R.; MacKay, R. J. Endotoxin-neutralizing activity of polymyxin B in blood after iv administration in horses. Am. J. Vet. Res., 2006, 67, 642.
110. Barton, M.H. Use of Polymyxin B for treatment of endotoxemia in horses. Compend. Cont. Educ. Pract. Vet., 2000, 22, 1056.
111. Barton, M. H.; Parviainen, A.; Norton, N. Polymyxin B protects horses against induced endotoxaemia in vivo. Equine Vet. J., 2004, 36, 397.
112. Parviainen, A. K.; Barton, M.; H.; Norton, N. N. Evaluation of polymyxin B in an ex vivo model of endotoxemia in Horses. Am. J. Vet. Res., 2001, 62, 72.
113. MacKay, R. J.; Clark, C. K.; Logdberg, L.; Lake, P. Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia. Am. J. Vet. Res., 1999, 60, 68.
114. Sentürk, S. Evaluation of the anti-endotoxic effects of polymyxin E (colistin) in dogs with naturally occurred endotoxic shock. J. Vet. Pharmacol. Ther., 2005, 28, 57.
115. Coppi, G.; Bondi, M.; Coppi, A.; Rossi, T.; Sergi, S.; Iannuccelli, V. Toxicity and gut associated lymphoid tissue translocation of polymyxin B orally administered by alginate/chitosan microparticles in rats. J. Pharm. Pharmacol., 2008, 60, 21.
116. Coppi, G.; Sala, N.; Bondi, M.; Sergi, S.; Iannuccelli, V. Ex-vivo evaluation of alginate microparticles for Polymyxin B oral administration. J. Drug Target., 2006, 14, 599.
117. Alipour, M.; Halwani, M.; Omri, A.; Suntres, Z. E. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gramnegative bacterial strains. Int. J. Pharm., 2008, 355, 293.
118. McAllister, S. M.; Alpar, H. O.; Brown, M. R. W. Antimicrobial properties of liposomal polymyxin B. J. Antimicrobial Chemother., 43, 1999, 203.
119. Pattani, A. S., Mandawgade, S. D., Patravale, V .B. Development and comparative anti-microbial evaluation of lipid nanoparticles and nanoemulsion of polymyxin B. J. Nanosci. Nanotechnol., 2006, 6 (9-10), 2986.
120. Bou-Chacra, N.; Pinto, T. D. J. A.; Kaneko, T. M. Evaluation of preservative systems in opthalmic suspension of polymyxin B and dexamethasone by linear regression. Pharmazie, 2007, 62, 199.
121. Bou-Chacra, N.; Kaneko, T. M.; Pinto, T. D. J. A. Optimization of preservative system in ophthalmic suspension with dexamethasone and polymyxin B. Pharm. Ind., 2008, 70, 670.
122. Cao, G.; Ali, F. E. A.; Chiu, F.; Zavascki, A. P.; Nation, R. L.; Li, J. Development and validation of a reversed-phase highperformance liquid chromatography assay for polymyxin B in human plasma. J. Antimicrob. Chemother., 2008, 62, 10009.
123. Sasaki, H.; White, S. H. Aggregation behaviour of an ultra-pure lipopolysacharide that stimulates TLR-4 receptors. Biophys. J., 2008, 95, 986.
124. Brandenburg, K.; Garidel, P.; Howe, J.; Andrä, J.; Hawkins, L.; Koch, M. H. J.; Seydel, U. What can calorimetry tell us about changes of phospholipids and glycolipids. Thermochim. Acta, 2006, 445, 133.
125. Pristovšek, P.; Kidrič, J. Solution structure of Polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modelling study. J. Med. Chem., 1999, 42, 4604.
126. Wiese, A. Charakterisierung von Peptid/Protein-induzierten Permmeabilitätsänderungen mit rekonstituierten bakteriellen Membranen. Habilitationschrift, Christian-Albrecht-Universität zu Kiel. 2001.
127. Andrä, J.; Howe, J.; Garidel, P.; Rössle, M.; Richter, W.; Leiva-León, J.; Moriyon, I.; Bartels, R.; Gutsmann, T.; Brandenburg, K. Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins: Thermodynamic, biophysical and microbiological analysis. Biochem. J., 2007, 406, 297.
128. Thomas, C. J.; Surolia, A. Kinetics of the interaction of endotoxin with polymyxin B and its analogs: a surface plasmon resonance analysis. FEBS Lett., 1999, 445, 420.
129. Brandenburg, K.; David, A.; Howe, J.; Koch, M. H. J.; Andrä, J.; Garidel, P.; Temperature dependence of the binding of endotoxins to the polycationic peptides polymyxin B and its nonapeptide, Biophys. J., 2005, 88, 1845.
130. Howe, J.; Andrä, J.; Conde, R.; Iriarte, M.; Garidel, P.; Koch, M. H. J.; Gutsmann, T.; Moriyón, I.; Brandenburg, K. Thermodynamic analysis of the lipopolysaccharide-dependent resistance of Gramnegative bacteria against polymyxin B. Biophys. J, 2007, 92, 2796.
131. Howe, J.; Hammer, M. U.; Brandenburg, K. Calorimetric investigations of the effect of polymyxin B on different Gram-negative bacteria. Thermochim. Acta, 2007, 458, 34.
132. Brandenburg, K.; Moriyon, I.; Arraiza, M.D.; Lewark-Yvetot, G.; Koch, M. H. J.; Seydel, U. Biophysical investigations into the interaction of lipopolysaccharide with polymyxins. Thermochim. Acta, 2002, 382, 189.
133. Tsubery, H.; Ofek, I.; Cohen, S.; Eisenstein, M.; Fridkin, M. Modulation of the hydrophobic domain of polymyxin B nonapeptide: Effect on outermembrane permeabilization and lipopolysaccharide neutralization. Mol. Pharmacol., 2002, 62, 1036.
134. Tsubery, H.; Ofek, I.; Cohen, S.; Fridkin, M. Structure activity relationship study of polymyxin B nonapeptide. Adv. Exp. Med. Biol., 2000, 479, 219.
135. Tsubery, H.; Ofek, I.; Cohen, S.; Fridkin, M. The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: Studies on polymyxin B nonapeptide. Biochemistry, 2000, 39, 11837.
136. Thomas, C. J.; Gangadhar, B. P.; Surolia, N.; Surolia, A. Kinetics and mechanism of the Recognitnition of endotoxin by polymyxin B. J. Am. Chem. Soc., 1998, 120, 12428.
137. Thomas, C. J.; Surolia, N.; Surolia, A. Surface plasmon resonance studies resolve the enigmatic endotoxin neutralizing activity of polymyxin B. J. Biol. Chem., 1999, 274, 29624.
138. Yin, N.; Marshall, R. L.; Matheson, S.; Savage, P. B. Synthesis of lipid A derivatives and their interactions with polymyxin B and polymyxin B nonapeptide. J. Am. Chem. Soc., 2003, 125, 2426.
139. Brandenburg, K. Isothermal titration calorimetric investigations of endotoxin binding to macrophages and the inhibition by polymyxin B. Thermochim. Acta, 2004, 415, 63.
140. Srimal, S.; Surolia, N., Balasubramanian, S.; Surolia, A. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem. J., 1996, 315, 679.
141. Brandenburg, K.; Arraiza, M. D.; Lewark-Ivetot, G.; Moriyon, I.; Zähringer, U. The interaction of rough and smooth form lipopolysaccharides with polymyxins as studied by titration calorimetry. Thermochim. Acta, 2002, 394, 53.
142. Bhattacharijya, S.; David, S.A.; Mathan, V.I.; Balaram, P. Polymyxin B nonapeptide: conformations in water and in the lipopoplysaccharide-bound state determined by two-dimensional NMR and molecular dynamics. Biopolymer, 1997, 41, 251.
143. Roes, S.; Seydel, U.; Gutsmann, T. Probing the properties of lipopolysaccharide monolayers and their interaction with the antimicrobial peptide Polymyxin B by atomic force microscopy. Langmuir, 2005, 21, 6970.
144. Wiese, A.; Münsterman, M.; Gutsmann, T.; Lindner, B.; Kawahara, K.; Zähringer, U.; Seydel, U. Molecular mechanisms of Polymyxin B-membrane interactions: direct correlation between surface charge density and self-promoted uptake. J. Membr. Biol., 1998, 162, 127.
145. Gooderham, W. J.; Bains, M.; McPhee, J. B.; Wiegand, I.; Hancock, R. E. W. Induction by cationic antimicrobial peptides and involvement in intrinsic polymyxin and antimicrobial peptide resistance, biofilm formation, and swarming motility of PsrA in Pseudomonas aeruginosa. J. Bacteriol., 2008, 190, 5624.
146. Gutsmann, T. Biophysikalische Untersuchungen an Lipidmembranen und Proteinkomplexen. Habilitationschrift Christian-Albrechts-Universität zu Kiel 2006.
147. Gaugelavičius, R.; Bakiene, E.; Bamford, D. H. Stages of Polymyxin B interaction with the Escherichia coli cell envelope. Antimicrob. Agents Chemother., 2000, 44, 2969.
148. Schröder, G.; Brandenburg, K.; Seydel, U. Polymyxin B induces transient permeability fluctuations in asymmetric planar lipopolysaccharide/ phospholipid bilayers. Biochemistry, 1992, 31, 631.
149. Garidel, P.; Hildebrand, A.; Knauf, K.; Blume, A. Membranolytic activity of bile salts: Influence of biological membrane properties and composition Molecules, 2007, 12, 2292.
150. Heerklotz, H.; Seelig, J. Detergent-like action of the antibiotic peptide surfactin on lipid membranes. Biophys. J., 2001, 81, 1547.
151. Heerklotz, H.; Seelig, J. Leakage and lysis of lipid membranes induced by the lipopeptide surfactin. Eur. Biophys. J., 2007, 36, 305.
152. Straus, S. K.; Hancock, R. E. W. Mode of action of the new antibiotic for Gram-positive pathogens datomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta, 2006, 1758, 1215.
153. Jenssen, H.; Hamill, P.; Hancock, R. E. W. Peptide antimicrobial agents. Clin. Microbiol. Rev., 2006, 19, 491.
154. Hanulová, M.; Andrä, J.; Garidel, P.; Olak, C.; Howe, J.; Funari, S. S.; Gutsmann, T.; Brandenburg, K. Interaction of melittin with phospholipid- and lipopolysaccharide- containing model membranes. Anti-Infect. Agents Med. Chem., 2009, 8, 17.
155. Ferrari, D.; Pizzirani, C.; Gulinelli, S.; Callegari, G.; Chiozzi, P.; Idzko, M.; Panther, E.; Di Virgilio, F. Modulation of P2X7 receptor functions by polymyxin B: Crucial role of the hydrophobic tail of the antibiotic molecule. Br. J. Pharmacol., 2007, 150, 445.
156. Sahalan, A. Z.; Dixon, R. A. Role of the cell envelope in the antibacterial activities of polymyxin B and polymyxin B nonapeptide against Escherichia coli. Int. J. Antimicrob. Agents, 2008, 31, 224.